Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum

Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum

Reports on the therapeutic drug monitoring (TDM) of second- and third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer patients are limited and are required to improve the safety of EGFR-TKI therapy. Some EGFR-TKIs have active metabolit...

Full description

Bibliographic Details
Main Authors: Chishima, H. (Author), Hakamata, J. (Author), Ikemura, S. (Author), Ishikawa, E. (Author), Jibiki, A. (Author), Kawazoe, H. (Author), Kimura, M. (Author), Kuniyoshi, O. (Author), Muramatsu, H. (Author), Nakada, H. (Author), Nakajima, H. (Author), Nakamura, T. (Author), Nakaya, N. (Author), Sato, I. (Author), Suehiro, N. (Author), Suzuki, S. (Author), Yokoyama, Y. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
Active metabolites
Amino acids
Biological organs
Biomolecules
Diseases
Drug products
Enzymes
Epidermal growth factor receptors
Epidermal growth factor receptor-tyrosine kinase inhibitor
Epidermal growth factor receptor-tyrosine kinase inhibitors
Human serum
Lc.ms/ms
LC-MS/MS
LC-MS-MS
Liquid chromatography
Mass spectrometry
Metabolites
Non small cell lung cancer
Non-small cell lung cancer
Patient monitoring
Patient treatment
Precipitation (chemical)
Protein precipitation
Receptor-tyrosine kinase
Safety factor
Tyrosine kinase inhibitor
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items